# Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lym

Source: https://onco.cc/trials/nct04384484/  
OnCo record `nct04384484` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Loncastuximab tesirine, Rituximab, Gemcitabine in diffuse large b-cell lymphoma, run by ADC Therapeutics S.A., active and no longer recruiting.

## Summary

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma is a phase 3 interventional study registered as NCT04384484 by ADC Therapeutics S.A., with 440 participants enrolled, started 2020-09-16 and due to reach its primary completion in 2026-03-31. Interventions recorded: Loncastuximab Tesirine, Rituximab, Gemcitabine, Oxaliplatin. Conditions listed: Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04384484
- Phase: 3
- Setting: A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)
- Sponsor: ADC Therapeutics S.A.
- Enrolled: 440

## Sources

- ClinicalTrials.gov NCT04384484: https://clinicaltrials.gov/study/NCT04384484

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Loncastuximab tesirine](https://onco.cc/drugs/zynlonta/), [Rituximab](https://onco.cc/drugs/rituximab/)
- companies: [ADC Therapeutics](https://onco.cc/companies/adc-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct04384484.json